Corporate Profile

Rigel currently has the following product candidates in development: fostamatinib, an oral spleen tyrosine kinase (SYK) inhibitor, which is in Phase 3 clinical trials for ITP and initiating a Phase 2 clinical trial for IgA nephropathy (IgAN); R348, a topical JAK/SYK inhibitor, in a Phase 2 clinical trial for dry eye in ocular graft-versus-host disease (GvHD); two oncology product candidates in Phase 1 development with partners BerGenBio AG and Daiichi; and three preclinical programs with partners AstraZeneca for R256 in asthma, Bristol-Myers Squibb for TGF beta inhibitors in immuno-oncology and Aclaris Therapeutics for JAK inhibitors in dermatology.

Recent News

More »
11/03/15Rigel Announces Third Quarter 2015 Financial Results
- Conference Call and Webcast Today at 5:00 PM Eastern Time - SOUTH SAN FRANCISCO, Calif., Nov. 3, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today reported financial results for the third quarter and nine months ended September 30, 2015. "We are concentrating our efforts on the timely completion of our two Phase 3 studies with fostamatinib in immune thrombocytopenic purpura (ITP). We expect topline data from the first Phase 3 trial in the middle of 2016 with the seco... 
Printer Friendly Version
10/27/15Rigel Announces Conference Call and Webcast to Report Third Quarter 2015 Financial Results
SOUTH SAN FRANCISCO, Calif., Oct. 27, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq:RIGL) today announced that it will report its third quarter 2015 financial results after market close on Tuesday, November 3, 2015.  Rigel senior management will follow the announcement with a live conference call and webcast at 5:00pm Eastern Time (2:00pm Pacific Time) to discuss the financial results. Participants can access the live conference call by dialing 855-892-1489 (domestic) or 720-634-29... 
Printer Friendly Version
09/09/15Rigel and Aclaris Therapeutics International Sign License Agreement for JAK Inhibitors to Treat Skin Disorders
SOUTH SAN FRANCISCO, Calif., Sept. 9, 2015 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that Aclaris Therapeutics International Limited (ATIL), a wholly owned subsidiary of Aclaris Therapeutics, Inc., and Rigel have entered into an exclusive, worldwide license agreement for the development and commercialization of specified Rigel JAK inhibitors for the treatment of alopecia areata and other dermatological conditions. Under the license agreement, ATIL will assume ... 
Printer Friendly Version

Upcoming Events

More »

There are currently no events scheduled.

Stock Quote

RIGL (Common Stock)
ExchangeNASDAQ (US Dollar)
Change (%) + 0.10 (3.13%)
Data as of 11/27/15 1:00 p.m. ET   Refresh quote

Stock Chart

Stock chart for: RIGL.O.  Currently trading at $3.29 with a 52 week high of $5.20 and a 52 week low of $2.02.
Data provided by Nasdaq. Minimum 15 minutes delayed. View Attributions and Sources

E-mail Alerts

Sign up to receive e-mail alerts whenever Rigel Pharmaceuticals Inc. posts new information to the site. Just enter your e-mail address and click Submit.